Diclofenac 25mg/ml Injection Franchise in Ahmedabad

NSAID Pain Relief Injection Supplier in Bangalore

Decplist 25 Injection Distributor in Hyderabad

Fast-Acting Anti-inflammatory Injection Franchise in Jaipur

Musculoskeletal Pain Injectable Stockist in Mumbai
Diclofenac Injectable Export & Manufacturing in Chandigarh

Home/Products /diclofenac-25mg-ml-injection

Decplist 25 Injection

Composition : Diclofenac (25mg/ml) Injection

Dosage Form : Injection

Packaging Type : Ampule

Packaging : 10x2x5ml

Price : ₹1/-

Decplist 25 Injection contains Diclofenac 25mg/ml, a fast-acting NSAID injection used for rapid management of pain and inflammation. It is widely employed in hospitals for musculoskeletal pain, post-operative discomfort, acute injury, and soft tissue inflammation, delivering quicker relief than oral formulations.

The injection offers immediate absorption and onset of action, making it ideal for patients requiring urgent pain control. Its potent anti-inflammatory effect helps reduce swelling, redness, and tenderness, improving patient mobility and comfort during recovery.

For hospitals, emergency care units, and distributors, Decplist 25 Injection is a high-demand injectable NSAID, regularly required in orthopedic wards, post-surgical care, and outpatient procedures. Its predictable efficacy ensures continuous demand and steady market movement.

Adding Decplist 25 Injection to your product catalog strengthens your pain management and NSAID injectable segment, providing robust opportunities in hospital procurement, institutional supply, export markets, and third-party manufacturing. Its essential role in clinical pain care makes it a valuable and strategically important product for pharmaceutical distributors.

Read More

About the Product

Decplist 25 Injection contains Diclofenac 25mg/ml, a fast-acting NSAID injection used for rapid management of pain and inflammation. It is widely employed in hospitals for musculoskeletal pain, post-operative discomfort, acute injury, and soft tissue inflammation, delivering quicker relief than oral formulations.

The injection offers immediate absorption and onset of action, making it ideal for patients requiring urgent pain control. Its potent anti-inflammatory effect helps reduce swelling, redness, and tenderness, improving patient mobility and comfort during recovery.

For hospitals, emergency care units, and distributors, Decplist 25 Injection is a high-demand injectable NSAID, regularly required in orthopedic wards, post-surgical care, and outpatient procedures. Its predictable efficacy ensures continuous demand and steady market movement.

Adding Decplist 25 Injection to your product catalog strengthens your pain management and NSAID injectable segment, providing robust opportunities in hospital procurement, institutional supply, export markets, and third-party manufacturing. Its essential role in clinical pain care makes it a valuable and strategically important product for pharmaceutical distributors.

Some patients may experience nausea, vomiting, stomach pain, or mild headache. Rarely, gastrointestinal bleeding, liver or kidney dysfunction, or allergic reactions may occur.

It is indicated for the treatment of acute pain, inflammation, and swelling associated with musculoskeletal disorders, postoperative pain, or arthritis. It helps relieve pain and improve mobility in patients requiring rapid onset of action.

Use only under medical supervision. Avoid in patients with known hypersensitivity to diclofenac, history of peptic ulcer, or severe kidney/liver impairment. Take the dose exactly as prescribed and avoid prolonged use without a doctor’s guidance.

Store in a cool, dry place below 25°C, protected from light. Keep out of reach of children. Use the injection under proper medical supervision.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Strategic Advisory

Ms. Shiwani Dhiman

VP-Strategic Outreach & Engagement

Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.

View Professional Profile

Start Your Journey

Partner With Cafoli

Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our rapidly growing network of successful franchise partners and turn your ambitions into reality. Limited Territories Available — Don’t Miss Out!

Quick Navigation